Aptevo Therapeutics Inc. provided a program update for APVO711, a dual mechanism bispecific antibody leveraging its proprietary ADAPTIR® platform. APVO711 is designed to combine a checkpoint inhibitor with immune activation, showcasing the scientific versatility of Aptevo's pipeline.
In preclinical studies, APVO711 demonstrated dual anti-cancer functionality with broad solid tumor potential and favorable developability. The PD-L1 arm of the bispecific blocks the PD-1/PD-L1 pathway, a common immune evasion mechanism used by cancer cells.
Concurrently, the CD40 arm of APVO711 enhances T cell priming through the activation of the stimulatory receptor CD40 on antigen-presenting cells. This dual approach aims to both remove immune suppression and boost anti-tumor immune responses, addressing significant unmet needs in solid tumor treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.